REFRACTORY MULTIPLE MYELOMA
Clinical trials for REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radioactive antibody combo aims to control High-Risk myeloma
Disease control Not yet recruitingThis early-phase study tests a new approach for people with high-risk multiple myeloma, including those whose cancer has returned or not responded to treatment. Participants receive a radioactive antibody that targets and kills myeloma cells, followed by chemotherapy, radiation, …
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 10:05 UTC
-
New hope for tough myeloma: Two-Drug combo takes on relapsed disease
Disease control Not yet recruitingThis study compares a new two-drug combination (daratumumab and teclistamab) against standard three-drug treatments for people with high-risk multiple myeloma that has returned or not responded to initial therapy. About 80 adults who have had only one prior treatment line will be…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:04 UTC
-
New hope for relapsed myeloma: Two-Drug combo aims to outperform standard therapy
Disease control Not yet recruitingThis study tests a new combination of teclistamab and pomalidomide against the usual treatment (carfilzomib, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned after initial therapy. The goal is to see if the new combo is safe and can reduce cancer ce…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New hope for Hard-to-Treat myeloma: CAR T-Cells join forces with daratumumab
Disease control Not yet recruitingThis early-phase study tests a new treatment called FT836 CAR T-cell therapy combined with daratumumab in 12 adults with multiple myeloma that has returned or not responded to at least three prior treatments. The main goal is to check safety and find the right dose. Participants …
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 18, 2026 12:06 UTC